What is the recommended intravenous dosing regimen for caspofungin, including loading dose, maintenance dose, adjustments for weight, renal and hepatic impairment, and duration of therapy?

Caspofungin Intravenous Dosing

For adults, administer a 70-mg loading dose on Day 1, followed by 50 mg once daily as maintenance therapy, with dose adjustments required only for moderate hepatic impairment (35 mg daily) and when co-administered with CYP enzyme inducers (70 mg daily). 1

Standard Adult Dosing (≥18 years)

Loading and Maintenance Doses

• Loading dose: 70 mg IV on Day 1
• Maintenance dose: 50 mg IV once daily starting Day 2
• Administration: Infuse slowly over approximately 1 hour; never give as IV bolus 1

Indication-Specific Durations

Candidemia and invasive candidiasis:

• Continue for at least 14 days after last positive culture 2, 1
• Extend therapy in persistently neutropenic patients 1

Esophageal candidiasis:

• 50 mg once daily for 7-14 days after symptom resolution (no loading dose studied for this indication) 1

Invasive aspergillosis:

• Duration based on disease severity, immunosuppression recovery, and clinical response 1

Empirical therapy in febrile neutropenia:

• Continue until neutropenia resolves
• If fungal infection confirmed, treat minimum 14 days after last positive culture and at least 7 days after neutropenia and symptoms resolve 1

Endocarditis (native or prosthetic valve):

• High-dose regimen: 150 mg daily for initial therapy 2
• Continue at least 6 weeks post-valve replacement 2

Weight-Based Adjustments

Adults with inadequate response:

• If 50 mg dose well-tolerated but insufficient clinical response, increase to 70 mg daily 1

Important caveat: Recent evidence suggests body weight significantly affects caspofungin exposure in ICU patients, with higher body weight (≥70-80 kg) associated with decreased drug concentrations 3, 4. While FDA labeling doesn't mandate routine weight-based adjustments, consider 70 mg maintenance dose for ICU patients >80 kg to achieve adequate pharmacokinetic targets 4.

Pediatric Dosing (3 months to 17 years)

BSA-based dosing:

• Loading dose: 70 mg/m² on Day 1 (maximum 70 mg)
• Maintenance dose: 50 mg/m² once daily (maximum 70 mg)
• Calculate BSA using Mosteller Formula 1

Dose escalation: If 50 mg/m² well-tolerated but inadequate response, increase to 70 mg/m² daily (not exceeding 70 mg absolute dose) 1

Critical consideration: Recent data suggests a BSA cut-off of 1.3 m² may optimize dosing—fixed loading dose preferred when BSA ≥1.3 m², BSA-based when <1.3 m² 5. For adolescents, maintenance dose of 60 mg/m²/day may achieve better trough concentrations 5.

Hepatic Impairment Adjustments

Mild impairment (Child-Pugh 5-6):

• No adjustment needed 1

Moderate impairment (Child-Pugh 7-9):

• Loading dose: 70 mg on Day 1 (unchanged)
• Maintenance dose: 35 mg once daily 1

Severe impairment (Child-Pugh >9):

• No clinical data available; use with caution 1

Critical Controversy: Hepatic Dosing in ICU Patients

The FDA-recommended dose reduction to 35 mg for Child-Pugh B patients is increasingly challenged by clinical evidence. Multiple recent studies demonstrate that this reduction results in subtherapeutic exposure, particularly in ICU patients where hypoalbuminemia (not true cirrhosis) drives the Child-Pugh score 6, 4, 7.

Key evidence:

• ICU patients with Child-Pugh B receiving 35 mg achieved only 14% pharmacokinetic target attainment versus 47% with standard 50 mg dosing 4
• Real-world data from 258 cirrhotic patients (Child-Pugh B and C) showed standard dosing was safe and effective with 53.1% favorable response and no hepatotoxicity requiring dose adjustment 7
• Pharmacokinetic studies found only marginal clearance reduction in decompensated cirrhosis 6

Practical recommendation: In non-cirrhotic ICU patients with elevated Child-Pugh scores driven by hypoalbuminemia, maintain standard 70/50 mg dosing. Only reduce to 35 mg in true moderate cirrhosis with preserved albumin 6, 4.

Renal Impairment

No dose adjustment required for any degree of renal dysfunction, including dialysis patients 1. Caspofungin is not dialyzable; no supplementary dosing needed post-hemodialysis 1.

CRRT patients: Standard dosing appropriate—CRRT clearance is negligible (0.042-0.048 L/h) 8. However, consider 100 mg loading dose followed by weight-based maintenance (50 mg for ≤80 kg, 70 mg for >80 kg) to achieve optimal targets in critically ill patients 8.

Drug Interaction Adjustments

CYP enzyme inducers requiring dose increase:

Adults:

• Rifampin: Increase to 70 mg once daily 1
• Consider 70 mg daily with: efavirenz, nevirapine, carbamazepine, dexamethasone, phenytoin 1

Pediatrics:

• Rifampin: Increase to 70 mg/m² daily (maximum 70 mg) 1
• Consider 70 mg/m² daily with other CYP inducers listed above 1

Common Pitfalls to Avoid

1. Don't reflexively reduce dose in ICU patients with hypoalbuminemia-driven Child-Pugh B scores—this creates subtherapeutic exposure 6, 4

2. Don't underdose obese patients—body weight >80 kg significantly reduces drug exposure; consider 70 mg maintenance dose in ICU patients 3, 4

3. Don't give bolus injections—always infuse over 1 hour to avoid infusion-related reactions 1

4. Don't stop therapy prematurely—continue at least 14 days after documented clearance and symptom resolution to prevent relapse 2, 1

5. Don't forget loading dose—except for esophageal candidiasis, always give 70 mg Day 1 loading dose to rapidly achieve therapeutic concentrations 1